Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 2, 2009, Pages 214-221

  Molavi, Ommoleila ^a   Ma, Zengshuan ^a   Hamdy, Samar ^a   Lavasanifar, Afsaneh ^a   Samuel, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

7 acyl lipid A; JSI 124; STAT3; Tumor immunosuppression

Indexed keywords

CUCURBITACIN; JSI 124; LIPID A; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CUCURBITACIN I; GLYCOLIC ACID DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG INHIBITION; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; MODULATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; MELANOMA, EXPERIMENTAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; GLYCOLATES; IMMUNE TOLERANCE; INJECTIONS, INTRALESIONAL; LIPID A; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TRITERPENES; LACTIC ACID; POLYGLYCOLIC ACID;

MUS;

EID: 70350644891     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970802380452     Document Type: Article

References (37)

1. M. A. Morse; S. Chui; A. Hobeika; H. K. Lyerly; T. Clay. Recent developments in therapeutic cancer vaccines. Nat Clin Prac Oncol. 2005; 2 (2):108-113
2. J. Samuel; W. A. Budzynski; M. A. Reddish; L. Ding; G. L. Zimmermann; M. J. Krantz; R. R. Koganty; B. M. Longenecker. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer. 1998; 75 (2):295-302.
3. B. Acres; S. Paul; H. Haegel-Kronenberger; B. Calmels; P. Squiban. Therapeutic cancer vaccines. Curr Opin Mol Ther. 2004; 6 (1):40-47
4. S. A. Rosenberg; J. C. Yang; N. P. Restifo. Cancer immunotherapy: Moving beyond current vaccines. Nat Med. 2004; 10 (9):909-915
5. P. Neeson; Y. Paterson. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. Immunol Invest. 2006; 35 (3-4):359-394
6. A. J. Muller; P. A. Scherle. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006; 6 (8):613-625
7. Q. Chen; W. C. Wang; S. S. Evans. Tumor microvasculature as a barrier to antitumor immunity. Cancer. Immunol Immunother. 2003; 52 (11):670-679
8. H. Yu; M. Kortylewski; D. Pardoll. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7 (1):41-51.
9. H. Yu; R. Jove. The STATs of cancer:New molecular targets come of age. Nat Rev Cancer. 2004; 4 (2):97-105.
10. M. Kortylewski; R. Jove; H. Yu. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis.ev. 2005; 24 (2):315-327
11. T. Wang; G. Niu; M. Kortylewski; L. Burdelya; K. Shain; S. Zhang; R. Bhattacharya; D. Gabrilovich; R. Heller; D. Coppola; W. Dalton; R. Jove; D. Pardoll; H. Yu. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10 (1):48-54.
12. M. Kortylewski; M. Kujawski; T. Wang; S. Wei; S. Zhang; S. Pilon- Thomas; G. Niu; H. Kay; J. Mule; W. G. Kerr; R. Jove; D. Pardoll; H. Yu. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11 (12):1314-1321
13. J. E. Jung; H. G. Lee; I. H. Cho; D. H. Chung; S. H. Yoon; Y. M. Yang; J. W. Lee; S. Choi; J. W. Park; S. K. Ye; M. H. Chung. STAT3 is a potential modulator of HIF1mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005; 19 (10):1296-1298
14. K. Srivastava; V. Kundumani-Sridharan; B. Zhang; A. K. Bajpai; G. N. Rao. 15(S)hydroxyeicosatetraenoic acidinduced angiogenesis requires STAT3dependent expression of VEGF. Cancer Res. 2007; 67 (9):4328-4336
15. S. Laxmanan; S. W. Robertson; E. Wang; J. S. Lau; D. M. Briscoe; D. Mukhopadhyay. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005; 334 (1):193-198
16. K. Mimura; K. Kono; A. Takahashi; Y. Kawaguchi; H. Fujii. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother. 2007; 56 (6):761-770
17. M. V. Dhodapkar; K. M. Dhodapkar; A. K. Palucka. Interactions of tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death Differ. 2008; 15 (1):39-50.
18. D. van Duin; R. Medzhitov; A. C. Shaw. Triggering TLR signaling in vaccination. Trends Immunol. 2006; 27 (1):49-55.
19. Y. C. Lu; W. C. Yeh; P. S. Ohashi. LPS/TLR4 signal transduction pathway. Cytokine. 2008; 42 (2):145-151
20. K. Takayama; E. Ribi; J. L. Cantrell. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res. 1981; 41 (7):2654-2657
21. P. Baldrick; D. Richardson; G. Elliott; A. W. Wheeler. Safety evaluation of monophosphoryl lipid A (MPL): An immunostimulatory adjuvant. Regul Toxicol Pharmacol. 2002; 35 (3):398-413.
22. Z. H. Jiang; W. A. Budzynski; D. Qiu; D. Yalamati; R. R. Koganty. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity. Carbohydr Res. 2007; 342 (6):784-796
23. C. Pasare; R. Medzhitov. Toll pathwaydependent blockade of CD4+CD25+ T cellmediated suppression by dendritic cells. Science. 2003; 299 (5609):1033-1036
24. Y. Nefedova; P. Cheng; D. Gilkes; M. Blaskovich; A. A. Beg; S. M. Sebti; D. I. Gabrilovich. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol. 2005; 175 (7):4338-4346
25. M. A. Blaskovich; J. Sun; A. Cantor; J. Turkson; R. Jove; S. M. Sebti. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/ signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003; 63 (6):1270-1279
26. Y. Nefedova; S. Nagaraj; A. Rosenbauer; C. Muro-Cacho; S. M. Sebti; D. I. Gabrilovich. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic- selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005; 65 (20):9525-9535
27. S. Hamdy; P. Elamanchili; A. Alshamsan; O. Molavi; T. Satou; J. Samuel. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co- glycolic acid) nanoparticles. J Biomed Mater Res A. 2007; 81 (3):652-662
28. S. Hamdy; A. Haddadi; V. Somayaji; D. Ruan; J. Samuel. Pharmaceutical analysis of synthetic lipid Abased vaccine adjuvants in poly (D, L-lactic-co-glycolic acid) nanoparticle formulations. J Pharm Biomed Anal. 2007; 44 (4):914-923
29. M. B. Lutz; N. Kukutsch; A. L. Ogilvie; S. Rossner; F. Koch; N. Romani; G. Schuler. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Meth. 1999; 223 (1):77-92.
30. L. Burdelya; M. Kujawski; G. Niu; B. Zhong; T. Wang; S. Zhang; M. Kortylewski; K. Shain; H. Kay; J. Djeu; W. Dalton; D. Pardoll; S. Wei; H. Yu. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol. 2005; 174 (7):3925-3931
31. J. N. Blattman; P. D. Greenberg. Cancer immunotherapy: A treatment for the masses. Science. 2004; 305 (5681):200-205
32. Y. Naito; K. Saito; K. Shiiba; A. Ohuchi; K. Saigenji; H. Nagura; H. Ohtani. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58 (16):3491-3494
33. L. Zhang; J. R. Conejo-Garcia; D. Katsaros; P. A. Gimotty; M. Massobrio; G. Regnani; A. Makrigiannakis; H. Gray; K. Schlienger; M. N. Liebman; S. C. Rubin; G. Coukos. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348 (3):203-213
34. S. J. Piersma; E. S. Jordanova; M. I. van Poelgeest; K. M. Kwappenberg; J. M. van der Hulst; J. W. Drijfhout; C. J. Melief; G. G. Kenter; G. J. Fleuren; R. Offringa; S. H. van der Burg. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007; 67 (1):354-361
35. O. Molavi; Z. Ma; A. Mahmud; A. Alshamsan; J. Samuel; R. Lai; G. S. Kwon; A. Lavasanifar. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm. 2008; 347 (1-2):118-127
36. O. Molavi; Z. Ma; S. Hamdy; R. Lai; A. Lavasanifar; J. Samuel. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol. 2008;
37. B. Huang; J. Zhao; J. C. Unkeless; Z. H. Feng; H. Xiong. TLR signaling by tumor and immune cells: A double-edged sword. Oncogene. 2008; 27 (2):218-224